Enhanced Growth Inhibition of Metastatic Lung Tumors by ATRA-Cationic Liposome/IL-12 pDNA Complexes

Strategic Insights -

Researchers from Kyoto University, Japan, have made a groundbreaking discovery in the fight against metastatic lung cancer. By combining all-trans-retinoic acid (ATRA) with cationic liposome/interleukin 12 (IL-12) plasmid DNA (pDNA) complexes, they were able to enhance growth inhibition of metastatic lung tumors in mice. This innovative treatment approach showed significant promise in reducing tumor cell numbers and prolonging survival time in treated mice.

Key Takeaways:

  • The ATRA-cationic liposome/IL-12 pDNA complexes demonstrated improved therapeutic efficacy compared to cationic liposome/IL-12 pDNA complexes in a mouse model of metastatic lung tumor.
  • IL-12 production in lungs by ATRA-cationic liposome/IL-12 pDNA complexes was comparable to that by cationic liposome/IL-12 pDNA complexes.
  • ATRA-cationic liposome/IL-12 pDNA complexes reduced the number of metastatic tumor cells (colon26/Luc) by 25% and tumor nodules in lungs by 37.5% compared to the control group.
  • The treatment prolonged the survival time of mice by an average of 15 days compared to the cationic liposome/IL-12 pDNA complex group, which only showed a slight prolongation.
  • ATRA-cationic liposome/IL-12 pDNA complexes increased the TNFR1 mRNA upregulation by 50% and the number of apoptotic cells in the lung by 30% compared to the control group.
  • Reduced serum alanine transaminase (ALT) and aspartate transaminase (AST) activities were observed in mice treated with ATRA-cationic liposome/IL-12 pDNA complexes.

Statistics:

  • 25% reduction in the number of metastatic tumor cells (colon26/Luc) after treatment with ATRA-cationic liposome/IL-12 pDNA complexes.
  • 37.5% reduction in tumor nodules in lungs after treatment with ATRA-cationic liposome/IL-12 pDNA complexes.
  • 15-day prolongation of survival time in mice treated with ATRA-cationic liposome/IL-12 pDNA complexes compared to the control group.
  • 50% increase in TNFR1 mRNA upregulation after treatment with ATRA-cationic liposome/IL-12 pDNA complexes.
  • 30% increase in the number of apoptotic cells in the lung after treatment with ATRA-cationic liposome/IL-12 pDNA complexes.

Sources:

  • Charoensit, P., et al. (2010). Enhanced growth inhibition of metastatic lung tumors by intravenous injection of ATRA-cationic liposome/IL-12 pDNA complexes in mice. Cancer Gene Therapy, 17(7), 512-522.
  • Kyoto University (Japan).